Tigecycline Suppresses the Virulence Factors of Multidrug-Resistant Allowing Human Neutrophils to Act.

PURPOSE

To determine the ability of human neutrophils to kill multidrug-resistant (MDRAB) in the presence of tigecycline (TGC).

METHODS

Clinical isolates of MDRAB were cultured with human neutrophils and HO in the presence of TGC. The numbers of viable bacteria, catalase activity, gene expression at the K locus of the MDRAB, reactive oxygen species (ROS) production, and granule exocytosis in human neutrophils were determined.

RESULTS

There was a time-dependent increase in the numbers of MDRAB after co-culturing with human neutrophils, whereas there was a significant decrease in the MDRAB numbers when co-cultured with both, human neutrophils and TGC for 6 h. The presence or absence of TGC did not affect total ROS production or the expression of CD11b, CD15, and CD63 on human neutrophils occurred when co-cultured with MDRAB. TGC significantly suppressed catalase activity and gene expression at the K locus of MDRAB, and significantly reduced the thickness of the capsule. Additionally, the bacterial viability of TGC-treated MDRAB cultured with HO was lower than that without HO after 6 h of culture.

CONCLUSION

TGC significantly suppressed the expression of catalase and the capsule in MDRAB without adverse effects on neutrophil function, allowing human neutrophils to kill MDRAB. TGC is an effective antibiotic for treating MDRAB infections.